Copyright: ©Author(s) 2026.
World J Dermatol. Sep 16, 2026; 12(1): 121180
Published online Sep 16, 2026. doi: 10.5314/wjd.121180
Published online Sep 16, 2026. doi: 10.5314/wjd.121180
Table 2 Survival function at years 1, 2, 3, 4 and 5 for patients receiving secukinumab and guselkumab
| Drug | Measure | 12 months | 24 months | 36 months | 48 months | 60 months |
| Secukinumab (n = 87) | Patients on treatment/number of discontinuations | 62/5 | 43/4 | 34/5 | 25/3 | 15/1 |
| Secukinumab (n = 87) | Survival function (95%CI) | 82.8 (74.6-91.0) | 75.3 (65.5-85.0) | 67.9 (56.7-79.0) | 57.3 (44.5-70.0) | 49.3 (35.5-63.1) |
| Guselkumab (n = 62) | Patients on treatment/number of discontinuations | 50/2 | 23/1 | 11/0 | 3/0 | - |
| Guselkumab (n = 62) | Survival function (95%CI) | 98.2 (94.8-100) | 93.0 (85.2-100) | 87.7 (75.2-100) | 87.7 (79.5-95.9) | - |
- Citation: Borrás-Blasco J, Valcuende-Rosique A, Alcala R, Cornejo-Uixeda S. Long-term persistence comparison between guselkumab and secukinumab for the treatment of psoriasis. World J Dermatol 2026; 12(1): 121180
- URL: https://www.wjgnet.com/2218-6190/full/v12/i1/121180.htm
- DOI: https://dx.doi.org/10.5314/wjd.121180